معرفی
Nitya Bakshi, MBBS, MS, is an Associate Professor of Pediatrics at Yale School of Medicine with dual appointments in Pediatric Hematology & Oncology (primary) and Biomedical Informatics & Data Science (secondary). Her clinical specialty focuses on pediatric hematology and oncology, particularly the care of children and young adults with sickle cell disease.
Dr. Bakshi received her medical degree (MBBS) from Christian Medical College, Vellore in 2007 and completed a Master's degree in Clinical Research from the University of Pittsburgh in 2014. Her educational background has prepared her for both clinical practice and research in hematology.
Her research interests center on understanding chronic pain in sickle cell disease, with emphasis on personalized pain management strategies. She investigates integrative approaches to pain management, patient-reported outcomes, and the long-term effects of hematopoietic cell transplantation. Her work spans clinical trials, digital health interventions, and epidemiological studies aimed at improving quality of life for sickle cell patients.
Analysis of Dr. Bakshi's recent publications reveals a strong focus on innovative therapeutic approaches for sickle cell disease pain management, including arginine therapy, cognitive-behavioral digital interventions, and multimodal treatment strategies. Her research increasingly examines the long-term outcomes of hematopoietic cell transplantation and the impact of sickle cell disease on patients' daily lives and quality of life.
Dr. Bakshi serves as a Sub Investigator for multiple clinical trials at Yale, including studies on sodium thiosulfate for cisplatin-induced ototoxicity, novel therapies for relapsed AML, and randomized trials comparing different management approaches for pediatric cancers. Her research has been consistently funded by NIH extramural grants.
She is actively involved in the STELLAR (Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry) research group, which investigates long-term outcomes after hematopoietic cell transplantation for sickle cell disease compared to non-transplanted individuals with sickle cell disease and their siblings without the condition.